The Winlevi Way

Hypothetical WINLEVI® (clascoterone cream 1%) Patients

Models shown are not actual patients.
*The exact mechanism of WINLEVI in acne vulgaris is unknown.1

A first-in-class mechanism to target androgen receptors in acne vulgaris1,2*

Female & Male

WINLEVI (clascoterone) cream 1% is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

WINLEVI® (clascoterone cream 1%) Co-Pay Card

Discover savings for eligible commercially insured patients

Learn More
A different way to treat acne    •

FDA-approved WINLEVI is the first novel topical mechanism for acne in 40 years2-4*

Targeting the effects of hormones in the skin

As you know, androgen hormones can cause acne in both females AND males by stimulating sebum production and inflammation.5 First-in-class WINLEVI (clascoterone) cream 1% is an FDA-approved novel topical androgen receptor inhibitor appropriate for use in both female AND male patients.1-4

WINLEVI is not like other acne treatments. Topical WINLEVI treats acne differently. And that could make a real difference to your patients.

Models shown are not actual patients.

Inhibits effects of androgen hormones on cells in sebaceous glands1,3,6
Significantly reduces inflammatory and noninflammatory lesions1,3
7% to 12% of patients experienced erythema/reddening, pruritus and scaling/dryness1,3†
No systemic side effects related to androgen inhibition3‡
Approved for female AND male patients aged 12 and up1,3

*The exact mechanism of WINLEVI in acne vulgaris is unknown.1

Additionally, edema, stinging, and burning occurred in >3% of patients and were reported in a similar percentage of subjects treated with vehicle.

In a maximum-use PK study in 42 patients, hypothalamic-pituitary-adrenal (HPA) axis suppression was observed in 5% (1/20) of adults (6 g BID) and 9% (2/22) of adolescents (4 g BID) at Day 14. All patients returned to normal HPA axis function at follow-up 4 weeks after the end of treatment.7 Attempt to withdraw use if HPA axis suppression develops.1

Models shown are not actual patients.